Amped PCR Secures Joint Investment To Develop PurifAI
Ben Davis, Founder & CEO, Amped PCR and PurifAI Inventor
Amped PCR has secured a joint investment from SFC Capital and the Development Bank of Wales (DBW) to advance their innovative pathogen detection solution, PurifAI.
Linzi Plant from the Development Bank of Wales, who played a key role in closing the round, said, “It was a pleasure to work with Ben and Aysha at Amped PCR. The potential uses of their product are huge and it’s fantastic to see a small Welsh company coming up with what could be a revolutionary solution in so many fields.”
Michael Theodosiou, Portfolio Analyst at SFC Capital, added, “We are thrilled to support Amped PCR as they revolutionise pathogen detection. PurifAI is a game-changing technology with the potential to significantly enhance safety and efficiency across multiple industries.”
PurifAI is an automated, deployable lab that detects dangerous pathogens in under four hours, addressing the critical need for faster, more reliable testing. Traditional methods often take days or weeks, leading to delays that risk costly recalls, waste and illness.
By enabling rapid, accurate testing, PurifAI enhances safety, minimises downtime and helps companies deliver safer products more efficiently. Its versatile capabilities are tailored towards the food safety industry, agriculture, veterinary diagnostics and environmental monitoring.
Amped PCR’s expertise in molecular diagnostics combined with strong industry partnerships positions the company to support businesses in adopting this groundbreaking solution.
Ben Davis, founder of Amped PCR, said: "This investment marks a pivotal moment as we bring PurifAI to market. We’re excited to work with our investors to deliver faster, smarter pathogen detection that will truly make a difference."
PurifAI Automation
